ConductScience.org, home

Paper31322224

Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin.

Deng M and 8 others. Mol Med Rep, 2019. Cited by 35 papers, by iCite.

Cite this record

ConductScience Library. Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin. Papers, record 31322224. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31322224

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin.
PubMed
Journal
Mol Med Rep
PubMed
Year
2019
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
35
iCite
Relative citation ratio, by iCite
1.37
iCite
Revised in PubMed
2020-02-25
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Deng MMinjie
2Sun JJiajun
3Xie SSuhong
4Zhen HHui
5Wang YYanchun
6Zhong AAiling
7Zhang HHongqin
8Lu RRenquan
9Guo LLin

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
CarboplatinMajor topic
Minichromosome Maintenance Complex Component 2Major topic
Ovarian NeoplasmsMajor topic
RNA InterferenceMajor topic
Apoptosis
Cell Line, Tumor
DNA Damage
Female
Humans
RNA, Small Interfering

Source PubMed

Download CSV of topics

References52

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110065148The dual role model for p53 in maintaining genomic integrity.Cell Mol Life Sci1999https://conductscience.org/library/papers/10065148PubMed
210101801p53 and apoptosis.Semin Cancer Biol1998https://conductscience.org/library/papers/10101801PubMed
310459007Mcm2, but not RPA, is a component of the mammalian early G1-phase prereplication complex.J Cell Biol1999https://conductscience.org/library/papers/10459007PubMed
410665656Cisplatin-resistant HeLa cells are resistant to apoptosis via p53-dependent and -independent pathways.Jpn J Cancer Res1999https://conductscience.org/library/papers/10665656PubMed
510697522De novo deletions of p53 gene and wild-type p53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line.Anticancer Res1999https://conductscience.org/library/papers/10697522PubMed
611493639DNA replication licensing and human cell proliferation.J Cell Sci2001https://conductscience.org/library/papers/11493639PubMed
711577478Cancer statistics, 2001.CA Cancer J Clin2001https://conductscience.org/library/papers/11577478PubMed
811774736p53 gene status and chemosensitivity in ovarian cancer.Hum Cell2001https://conductscience.org/library/papers/11774736PubMed
912045100DNA replication in eukaryotic cells.Annu Rev Biochem2002https://conductscience.org/library/papers/12045100PubMed
1012539237Paradoxes of eukaryotic DNA replication: MCM proteins and the random completion problem.Bioessays2003https://conductscience.org/library/papers/12539237PubMed
1112901728Minichromosome maintenance 2 expression is correlated with mode of invasion and prognosis in oral squamous cell carcinomas.J Oral Pathol Med2003https://conductscience.org/library/papers/12901728PubMed
1214612534Inhibiting the expression of DNA replication-initiation proteins induces apoptosis in human cancer cells.Cancer Res2003https://conductscience.org/library/papers/14612534PubMed
1314635251Perpetuating the double helix: molecular machines at eukaryotic DNA replication origins.Bioessays2003https://conductscience.org/library/papers/14635251PubMed
1414661040Primary ovarian cancer chemotherapy: current standards of care.Br J Cancer2003https://conductscience.org/library/papers/14661040PubMed
1515007098Eukaryotic MCM proteins: beyond replication initiation.Microbiol Mol Biol Rev2004https://conductscience.org/library/papers/15007098PubMed
1615083189A novel immunohistochemical method for estimating cell cycle phase distribution in ovarian serous neoplasms: implications for the histopathological assessment of paraffin-embedded specimens.Br J Cancer2004https://conductscience.org/library/papers/15083189PubMed
1715096526The role of Cdc6 in ensuring complete genome licensing and S phase checkpoint activation.J Cell Biol2004https://conductscience.org/library/papers/15096526PubMed
1815210935Minichromosome maintenance proteins are direct targets of the ATM and ATR checkpoint kinases.Proc Natl Acad Sci U S A2004https://conductscience.org/library/papers/15210935PubMed
1915538388Interaction between human MCM7 and Rad17 proteins is required for replication checkpoint signaling.EMBO J2004https://conductscience.org/library/papers/15538388PubMed
2015814627Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma.Clin Cancer Res2005https://conductscience.org/library/papers/15814627PubMed

See all 52 referencesDownload CSV of references

Cited by24

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 35 citations.

PMIDTitleJournalYearIn PapersSource
42975739Integrative multi-omics analysis reveals a GALNT6/Smad2/CDC7 axis promoting cisplatin resistance through enhanced DNA damage repair in bladder cancer.Funct Integr Genomics2026https://conductscience.org/library/papers/42975739PubMed
41940421Targeting KIF23 inhibits cell proliferation and primary chemoresistance in cervical cancer by inactivating the MYH9/MCM2/PCNA pathway.Clin Transl Med2026https://conductscience.org/library/papers/41940421PubMed
41795017CDK4/6i reverse PARPi resistance by targeting the E2F1- MCM2/5 pathway.NPJ Precis Oncol2026https://conductscience.org/library/papers/41795017PubMed
40440106Discovery and Mechanism of 16-19F, a Novel Synthetic Lethal Inhibitor of the PRMT5•MTA Complex in MTAP-Deleted Cancer Cells.ACS Chem Biol2025https://conductscience.org/library/papers/40440106PubMed
40248198Therapeutic potential of microRNA-506 in cancer treatment: mechanisms and therapeutic implications.Front Oncol2025https://conductscience.org/library/papers/40248198PubMed
40175339ABCB1 confers resistance to carboplatin by accumulating stem-like cells in the G2/M phase of the cell cycle in p53null ovarian cancer.Cell Death Discov2025https://conductscience.org/library/papers/40175339PubMed
39309198Proteomics and Bioinformatics Investigations Link Overexpression of FGF8 and Associated Hub Genes to the Progression of Ovarian Cancer and Poor Prognosis.Biochem Res Int2024https://conductscience.org/library/papers/39309198PubMed
38841623Immune-related gene methylation prognostic instrument for stratification and targeted treatment of ovarian cancer patients toward advanced 3PM approach.EPMA J2024https://conductscience.org/library/papers/38841623PubMed
37529110Hydroquinidine displays a significant anticarcinogenic activity in breast and ovarian cancer cells via inhibiting cell-cycle and stimulating apoptosis.Turk J Biol2023https://conductscience.org/library/papers/37529110PubMed
37480569KNTC1 and MCM2 are the molecular targets of gallbladder cancer.Aging (Albany NY)2023https://conductscience.org/library/papers/37480569PubMed
36776764DNA replication: Mechanisms and therapeutic interventions for diseases.MedComm (2020)2023https://conductscience.org/library/papers/36776764PubMed
36303105MCM2 in human cancer: functions, mechanisms, and clinical significance.Mol Med2022https://conductscience.org/library/papers/36303105PubMed
35924161Impairment of RAD17 Functions by miR-506-3p as a Novel Synthetic Lethal Approach Targeting DNA Repair Pathways in Ovarian Cancer.Front Oncol2022https://conductscience.org/library/papers/35924161PubMed
35693940Multi-Omics Analysis of MCM2 as a Promising Biomarker in Pan-Cancer.Front Cell Dev Biol2022https://conductscience.org/library/papers/35693940PubMed
35173548DNA Replication Licensing Factors: Novel Targets for Cancer Therapy via Inhibiting the Stemness of Cancer Cells.Int J Biol Sci2022https://conductscience.org/library/papers/35173548PubMed
35056094BI-2536 Promotes Neuroblastoma Cell Death via Minichromosome Maintenance Complex Components 2 and 10.Pharmaceuticals (Basel)2021https://conductscience.org/library/papers/35056094PubMed
34859821Multiomics profiling of the expression and prognosis of MCMs in endometrial carcinoma.Biosci Rep2021https://conductscience.org/library/papers/34859821PubMed
34670865GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress.Mol Cancer Res2022https://conductscience.org/library/papers/34670865PubMed
34440557Novel Therapies for Tongue Squamous Cell Carcinoma Patients with High-Grade Tumors.Life (Basel)2021https://conductscience.org/library/papers/34440557PubMed
34178669Systemic Analysis of the DNA Replication Regulator MCM Complex in Ovarian Cancer and Its Prognostic Value.Front Oncol2021https://conductscience.org/library/papers/34178669PubMed

See all 24 cited byDownload CSV of cited by

Genes8

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/31322224

GET https://conductscience.org/api/papers/v1/31322224/references?page=2